GALECTIN THERAPEUTICS INC. Fair Value Adjustment of Warrants
GALECTIN THERAPEUTICS INC. (GALT) reported Fair Value Adjustment of Warrants of $2.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-14
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $3.16M, a 187.96% increase year-over-year.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$983.00K, a 4032.00% decline year-over-year.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $220.00K.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was $2.21M, a 192.44% increase year-over-year.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2025 was $3.55M.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2024 was -$588.00K, a 236.11% decline from fiscal 2023.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2023 was $432.00K.
- GALECTIN THERAPEUTICS INC. fair value adjustment of warrants for fiscal 2022 was -$557.00K.
| Period end | Fair Value Adjustment of Warrants 0 month | Fair Value Adjustment of Warrants | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 156 month | Fair Value Adjustment of Warrants 159 month | Fair Value Adjustment of Warrants 162 month | Fair Value Adjustment of Warrants 165 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.17M 10-Q · filed 2026-08-14 | $2.39M derived: sum of 3 quarters · filed 2026-08-14 | $4.60M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2026-03-31 | -$983.00K 10-Q · filed 2026-05-15 | -$763.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.44M derived: sum of 3 quarters · filed 2026-05-15 | $2.54M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.42M derived: sum of 2 quarters · filed 2026-03-31 | $3.52M derived: sum of 3 quarters · filed 2026-08-14 | $3.55M 10-K · filed 2026-03-31 | ||||||
| 2025-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.30M derived: sum of 2 quarters · filed 2026-08-14 | $3.33M 10-Q · filed 2025-11-14 | $1.22M derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.12M 10-Q · filed 2026-08-14 | -$981.00K derived: sum of 3 quarters · filed 2026-08-14 | -$227.00K derived: sum of 4 quarters · filed 2026-08-14 | ||||||
| 2025-03-31 | $25.00K 10-Q · filed 2026-05-15 | -$2.08M derived: sum of 2 quarters · filed 2026-05-15 | -$1.32M derived: sum of 3 quarters · filed 2026-05-15 | -$1.43M derived: sum of 4 quarters · filed 2026-05-15 | ||||||
| 2024-12-31 | -$2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.35M derived: sum of 2 quarters · filed 2026-03-31 | -$1.46M derived: sum of 3 quarters · filed 2026-03-31 | -$588.00K 10-K · filed 2026-03-31 | ||||||
| 2024-09-30 | $754.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $646.00K derived: sum of 2 quarters · filed 2025-11-14 | $1.51M 10-Q · filed 2025-11-14 | $1.18M derived: sum of 4 quarters · filed 2025-11-14 | ||||||
| 2024-06-30 | -$108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $760.00K 10-Q · filed 2025-08-14 | $423.00K derived: sum of 3 quarters · filed 2025-08-14 | $913.00K derived: sum of 4 quarters · filed 2025-08-14 | ||||||
| 2024-03-31 | $868.00K 10-Q · filed 2025-05-15 | $531.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.02M derived: sum of 3 quarters · filed 2025-05-15 | $531.00K derived: sum of 4 quarters · filed 2025-05-15 | ||||||
| 2023-12-31 | -$337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $153.00K derived: sum of 2 quarters · filed 2025-03-31 | -$337.00K derived: sum of 3 quarters · filed 2025-03-31 | $432.00K 10-K · filed 2025-03-31 | ||||||
| 2023-09-30 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $769.00K 10-Q · filed 2024-11-14 | $492.00K derived: sum of 4 quarters · filed 2024-11-14 | ||||||
| 2023-06-30 | -$490.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $279.00K 10-Q · filed 2024-08-13 | $2.00K derived: sum of 3 quarters · filed 2024-08-13 | $226.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | $769.00K 10-Q · filed 2024-05-15 | $492.00K derived: sum of 2 quarters · filed 2024-05-15 | $716.00K derived: sum of 3 quarters · filed 2024-05-15 | $441.00K derived: sum of 4 quarters · filed 2024-05-15 | ||||||
| 2022-12-31 | -$277.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$53.00K derived: sum of 2 quarters · filed 2024-03-29 | -$328.00K derived: sum of 3 quarters · filed 2024-03-29 | -$557.00K 10-K · filed 2024-03-29 | ||||||
| 2022-09-30 | $224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$51.00K derived: sum of 2 quarters · filed 2023-11-13 | -$280.00K 10-Q · filed 2023-11-13 | -$756.00K derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | -$275.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$504.00K 10-Q · filed 2023-08-14 | -$980.00K derived: sum of 3 quarters · filed 2023-08-14 | -$814.00K derived: sum of 4 quarters · filed 2023-08-14 | ||||||
| 2022-03-31 | -$229.00K 10-Q · filed 2023-05-15 | -$705.00K derived: sum of 2 quarters · filed 2023-05-15 | -$539.00K derived: sum of 3 quarters · filed 2023-05-15 | -$367.00K derived: sum of 4 quarters · filed 2023-05-15 | ||||||
| 2021-12-31 | -$476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$310.00K derived: sum of 2 quarters · filed 2023-03-30 | -$138.00K derived: sum of 3 quarters · filed 2023-03-30 | -$138.00K 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | $166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $338.00K derived: sum of 2 quarters · filed 2022-11-14 | $338.00K 10-Q · filed 2022-11-14 | $338.00K derived: sum of 4 quarters · filed 2022-11-14 | ||||||
| 2021-06-30 | $172.00K 10-Q · filed 2021-08-16 | $172.00K 10-Q · filed 2022-08-15 | $172.00K derived: sum of 3 quarters · filed 2022-05-16 | $172.00K derived: sum of 4 quarters · filed 2022-05-16 | ||||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | $0.00 derived: sum of 3 quarters · filed 2022-05-16 | |||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $0.00 derived: sum of 2 quarters · filed 2022-03-31 | $0.00 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||||||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-16 | |||||||||
| 2014-03-31 | $0.00 derived: 10-Q 165 month − 10-K 162 month · filed 2014-05-13 | $0.00 derived: sum of 2 quarters · filed 2014-05-13 | $0.00 derived: sum of 3 quarters · filed 2014-05-13 | -$9.02M 10-Q · filed 2014-05-13 | ||||||
| 2013-12-31 | $0.00 derived: 10-K 162 month − 10-Q 159 month · filed 2014-03-21 | $0.00 derived: sum of 2 quarters · filed 2014-03-21 | -$9.02M 10-K · filed 2014-03-21 | |||||||
| 2013-09-30 | $0.00 derived: 10-Q 159 month − 10-Q 156 month · filed 2013-11-12 | -$9.02M 10-Q · filed 2013-11-12 | ||||||||
| 2013-06-30 | -$9.02M 10-Q · filed 2013-08-14 | |||||||||
| 2011-12-31 | $524.00K 10-K · filed 2014-03-21 | |||||||||
| 2008-06-30 | $356.00K 10-K · filed 2014-03-21 | |||||||||
| 2008-05-21 | $100.00K 10-K · filed 2014-03-21 | $100.00K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |